Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04616326 · ClinicalTrials.gov registry record · Phase 3

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

A Phase 3 study of Chronic Migraine, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
312
Enrollment target
20
Study locations

NCT04616326 is a Phase 3 study of Chronic Migraine that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 312 participants, roughly in line with the 325-participant average among 17 other Chronic Migraine trials with a reported enrollment target. The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04616326, a Phase 3 study of Chronic Migraine, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
312 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

Conditions Studied

Chronic Migraine

Interventions

  • DRUG Placebo
  • DRUG Galcanezumab

Study Locations (20)

Florida

  • Northwest Florida Clinical Research Group - Gulf Breeze
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
  • Vitaly Clinical Research - Miami
  • EMDA Clinical Research - Miami
  • Bio-Medical Research LLC - Miami
  • Allied Biomedical Research Institute - Miami
  • Ezy Medical Research - Miami Lakes
  • Wellness Clinical Research - Miami Lakes
  • Avanza Medical Research Center - Pensacola
  • D&H Tamarac Research Center - Tamarac
  • Infinity Life Research Group - Tamarac
  • USF Health - Tampa
  • Palm Beach Research Center - West Palm Beach

Arizona

  • 21st Century Neurology, a Division of Xenoscience, Inc. - Phoenix
  • Phoenix Children's Hospital - Phoenix
  • Center for Neurosciences - Tucson

Alabama

  • Rehabilitation & Neurological Services - Huntsville

California

  • Miller Children's & Women's Hospital Long Beach - Long Beach

Colorado

  • Children's Hospital Colorado - Aurora

Idaho

  • Medical Research Partners - Ammon

Trial Details

FieldValue
Enrollment Target 312 participants
Start Date 2020-11-25
Est. Completion 2027-03
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04616326

The ClinicalTrials.gov registry entry for NCT04616326 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 325-participant average among 17 other Chronic Migraine trials with a reported enrollment target. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04616326 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT04616326 about?

NCT04616326 is a clinical study titled "A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine". The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine he...

What is the current status of trial NCT04616326?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 2020-11-25. Estimated completion is 2027-03.

What conditions does trial NCT04616326 study?

This clinical trial studies the following conditions: Chronic Migraine.

What interventions are being tested in trial NCT04616326?

The interventions under investigation include: Placebo (DRUG), Galcanezumab (DRUG).

Who is sponsoring clinical trial NCT04616326?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04616326 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Migraine

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.